Xolair works by binding to and blocking IgE in the bloodstream, which reduces the immune system’s ability to mount a severe allergic response. This increases the threshold of reactivity — meaning a larger quantity of the allergen is needed to cause a reaction. It significantly reduces the risk of anaphylaxis from accidental exposure.
FAQs
Xolair (omalizumab) is an FDA-approved biologic medication that targets immunoglobulin E (IgE) — a key driver of allergic reactions. It has been used safely for more than 20 years in the treatment of severe asthma and chronic urticaria. In 2024, the FDA approved Xolair for the treatment of IgE-mediated food allergies in patients ages 1 and up.
Xolair works by binding to and blocking IgE in the bloodstream, which reduces the immune system’s ability to mount a severe allergic response. This increases the threshold of reactivity — meaning a larger quantity of the allergen is needed to cause a reaction. It significantly reduces the risk of anaphylaxis from accidental exposure.
Xolair is given as a subcutaneous (under-the-skin) injection in our office every 2 to 4 weeks. The frequency and dose are determined by your weight and total IgE level in the blood, measured before starting treatment.
No. Patients taking Xolair must continue to avoid their food allergens. Xolair reduces the risk of a reaction from accidental exposure — it does not eliminate the allergy or permit intentional consumption of the food.
Xolair’s protective effect is active only while you are receiving injections. Once treatment stops, IgE is no longer blocked and sensitivity returns. Your allergist will discuss the long-term plan with you.
Xolair may be the preferred option for patients who: have multiple food allergies, experience significant anxiety related to accidental exposure, or are not ideal candidates for the daily commitment of SLIT or OIT. It is approved starting at age 1, making it available to very young patients.
Xolair requires prior authorization from your insurance plan. Our team will work with you and your insurer to navigate the approval process before beginning treatment. Out-of-pocket costs vary by plan.
Xolair has a well-established safety profile developed over 20+ years of clinical use. As with any injectable medication, there is a small risk of allergic reaction at the injection site. All injections are administered in our office, where our team is equipped to monitor you. Do not receive Xolair if you are allergic to omalizumab.